Novartis AG (NVS) Announced Q1 2026 Earnings on April 28, 2026, Reporting "sales down 5% and core op inc down 14%"
Novartis AG announced Q1 2026 financial results, reporting a 5% decrease in sales and a 14% decrease in core operating income. Despite these declines, the company highlighted significant growth in key products such as Kisqali, Kesimpta, Pluvicto, Scemblix, and Leqvio, and…